Fine Foods & Pharmaceuticals N.T.M Past Earnings Performance
Past criteria checks 0/6
Fine Foods & Pharmaceuticals N.T.M's earnings have been declining at an average annual rate of -51.3%, while the Life Sciences industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 10.7% per year.
Key information
-51.3%
Earnings growth rate
-50.5%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 10.7% |
| Return on equity | -2.8% |
| Net Margin | -1.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Is There An Opportunity With Fine Foods & Pharmaceuticals N.T.M. S.p.A.'s (BIT:FF) 40% Undervaluation?
Apr 28
Estimating The Fair Value Of Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF)
Mar 20Something To Consider Before Buying Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF) For The 1.1% Dividend
Feb 22A Look At Fine Foods & Pharmaceuticals N.T.M's (BIT:FF) Share Price Returns
Feb 01What You Need To Know About Fine Foods & Pharmaceuticals N.T.M. S.p.A.'s (BIT:FF) Investor Composition
Jan 14We Wouldn't Rely On Fine Foods & Pharmaceuticals N.T.M's (BIT:FF) Statutory Earnings As A Guide
Dec 28Is Fine Foods & Pharmaceuticals N.T.M (BIT:FF) Using Too Much Debt?
Dec 08Revenue & Expenses BreakdownBeta
How Fine Foods & Pharmaceuticals N.T.M makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 252 | -4 | 45 | 0 |
| 30 Sep 23 | 240 | 1 | 43 | 0 |
| 30 Jun 23 | 234 | -5 | 42 | 0 |
| 31 Mar 23 | 222 | -4 | 40 | 0 |
| 31 Dec 22 | 207 | -10 | 39 | 0 |
| 30 Sep 22 | 203 | -10 | 39 | 0 |
| 30 Jun 22 | 196 | -1 | 38 | 0 |
| 31 Mar 22 | 194 | -6 | 36 | 0 |
| 31 Dec 21 | 195 | -1 | 35 | 0 |
| 30 Sep 21 | 198 | -1 | 35 | 0 |
| 30 Jun 21 | 200 | 2 | 34 | 0 |
| 31 Mar 21 | 190 | 13 | 33 | 0 |
| 31 Dec 20 | 177 | 13 | 31 | 0 |
| 30 Sep 20 | 162 | 8 | 28 | 0 |
| 30 Jun 20 | 153 | -1 | 27 | 0 |
| 31 Mar 20 | 157 | -2 | 28 | 0 |
| 31 Dec 19 | 161 | -3 | 28 | 0 |
| 30 Sep 19 | 157 | 8 | 29 | 0 |
| 30 Jun 19 | 153 | 9 | 29 | 0 |
| 31 Mar 19 | 147 | 9 | 28 | 0 |
| 31 Dec 18 | 140 | 9 | 26 | 0 |
Quality Earnings: FF is currently unprofitable.
Growing Profit Margin: FF is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FF is unprofitable, and losses have increased over the past 5 years at a rate of 51.3% per year.
Accelerating Growth: Unable to compare FF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FF is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (6.5%).
Return on Equity
High ROE: FF has a negative Return on Equity (-2.77%), as it is currently unprofitable.